Gross Profit Analysis: Comparing Vertex Pharmaceuticals Incorporated and BioMarin Pharmaceutical Inc.

Vertex vs. BioMarin: A Decade of Biotech Growth

__timestampBioMarin Pharmaceutical Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014621276000519428000
Thursday, January 1, 2015737887000906794000
Friday, January 1, 20169072340001491717000
Sunday, January 1, 201710718600002213533000
Monday, January 1, 201811759480002638058000
Tuesday, January 1, 201913445820003615063000
Wednesday, January 1, 202013361830005469383000
Friday, January 1, 202113757600006670200000
Saturday, January 1, 202216123700007850400000
Sunday, January 1, 202318421610008607000000
Monday, January 1, 202422736800009489600000
Loading chart...

In pursuit of knowledge

A Decade of Growth: Vertex vs. BioMarin

In the competitive landscape of biotechnology, Vertex Pharmaceuticals Incorporated and BioMarin Pharmaceutical Inc. have emerged as key players. Over the past decade, Vertex has demonstrated a remarkable growth trajectory, with its gross profit increasing by over 1,500% from 2014 to 2023. This surge is largely attributed to its innovative treatments for cystic fibrosis, which have dominated the market.

Conversely, BioMarin has shown steady growth, with a gross profit increase of nearly 200% during the same period. Known for its focus on rare genetic diseases, BioMarin's consistent performance underscores its strategic investments in niche markets.

By 2023, Vertex's gross profit was approximately 4.7 times that of BioMarin, highlighting its aggressive expansion and market penetration. This analysis not only reflects the dynamic nature of the biotech industry but also underscores the importance of strategic innovation and market focus.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025